Sparks commentary - Herantis Pharma

Healthcare

Sparks - Herantis Pharma

More on this equity
Herantis (OMX: HRTIS) – Phase Ib study starts dosing in final cohort
Published by Arron Aatkar, PhD

Herantis Pharma has announced that the first patients have been dosed in the final cohort of its Phase Ib trial, which is assessing its lead clinical candidate, HER-096, in patients with Parkinson’s disease (PD). The study is currently in Part 2, the randomised, placebo-controlled portion of the trial and the first test of HER-096 in PD patients. The primary endpoint is based on safety, tolerability and the pharmacokinetics of repeated doses of the candidate. The Part 2 portion is also evaluating biomarkers. Results are on track to be reported in September 2025 and could represent a major upcoming catalyst for Herantis.

HER-096 is a peptide mimic of the protein CDNF. Importantly, HER-096 has been shown to cross the blood-brain barrier and, with its novel multi-pronged mechanism of action, holds promise as a potential disease-modifier for PD.

Latest

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free